Hartford Business

Alexion Seeks FDA Approval of Soliris for Refractory Myasthenia Gravis
Rare Disease Report
Myasthenia gravis often starts out as weakness in the ocular muscles but at the disease progresses to more generalized form, it can weaken head, neck, trunk, limb and respiratory muscles. Myasthenia gravis is an autoimmune disease in which antibodies ...
Soliris Application Seeks Ultra-Rare Neuromuscular Disease IndicationMonthly Prescribing Reference (registration)
Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with ...Business Wire (press release)
Alexion seeks to market drug for neuromuscular diseaseHartford Business
Seeking Alpha
all 5 news articles »

Janesville Gazette

New group supports people with myasthenia gravis
Janesville Gazette
Joseph Ryder of Milto, was diagnosed with myasthenia gravis in 2007 after one of his eyelids began to droop. Ryder has tried since 2009 to form a support group for the disease, a chronic autoimmune neuromuscular disorder that causes weakness in the ...


This loving 12-year-old boy died after suffering an extremely rare ...
Matthew Knowles had been diagnosed with Myasthenia Gravis - a rare autoimmune condition - a year before his death.

and more »

argenx launches Phase II proof-of-concept study of ARGX-113 for ...
P&T Community
Topline data from the study expected in second half of 2018 - 9 January 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), ...

and more »


Alexion Applies for Expanded Use of Soliris (ALXN) | Investopedia
Alexion files for label expansion for its drug Soliris in both the US and the EU.

and more »

Report explores the myasthenia gravis epidemiology market outlook to 2023
Latest report on Myasthenia Gravis Industry provides essential information for business growth. It shows the market trends, manufacturing processes, cost structures, import-export, supply, production, revenue growth rate, major manufacturers and more.

argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis
GlobeNewswire (press release)
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, ...

Review Fortune

What directions Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) insiders are heading
Review Fortune
... Administration (FDA) and the European Medicines Agency (EMA) to extend the indication for Soliris® (eculizumab) as a treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody ...
Insider Trading in the Spotlight: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)The Voice Registrar

all 54 news articles »


Alexion's Soliris Fails Kidney Transplant Trial (ALXN)
Though Soliris failed in the latest organ-transplant trial, Alexion has other ongoing expansion efforts for Soliris. It is being tested to treat myasthenia gravis, a neuromuscular disorder leading to weakness and rapid fatigue of muscles under ...
Troubled Alexion takes another hit as star drug Soliris falls short in transplant trialFiercePharma

all 113 news articles »


Rituximab Effective, Durable in Refractory Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
Many current treatments for myasthenia gravis (MG) are nonspecific immunotherapeutics, to which a subset of patients is medically refractory. Previous studies have suggested that B-cell–targeted treatment with rituximab has efficacy in MG, but the ...

Google News